Lucentis & VisudyneStudy of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD

Inclusion Criteria:

• Ability to give informed consent
• Treatment- naïve patients with active, subfoveal, exudative AMD
• Patients with visual acuity of 20/40-20/320 in the study eye
• Subfoveal choroidal neovascularization (CNV) must be at least 50% of the total lesion size Total area of lesion components other that CNV must be less than 50% of the total lesion size
• The lesion must be < 5400microns in greatest linear dimension (GLD)
• Lesion size < 10 DA
• Occult with no classic CNV lesions must have presumed recent disease progression:

1. Blood associated with the lesion at baseline
2. Loss of visual acuity in the previous 3 months: a: > 5 letter loss (ETDRS equivalent) or b: 2 or more lines using a snellen or equivalent chart
3. > 10% increase in GLD as assessed by fluorescein angiography in the previous 3 months

• Previous treatment for CNV with anti-VEGF agents, intraocular steroids and/or Photodynamic therapy with Visudyne® in the study eye
• Geographic atrophy or fibrosis in the study eye
• Intraocular surgery within 6 weeks of enrollment
• Subretinal hemorrhage > 50% of the total lesion
• Patients with intraocular pressure greater than 30 mm/Hg on 2 pressure-lowering medications
• Patients with severe disciform scarring.
• Inability to make study visits
• Advanced glaucoma
• Allergies to porfins or a known hypersensitivity to any component of Visudyne®
• Patients with porphyria
• Pregnancy or lactation